Cumberland Pharmaceuticals Shares Updated Trial Results For Duchenne Muscular Dystrophy Heart Disease Treatment Showing A 30% Reduction In MYL3 And 50% Reduction In MYOD1 With A Favorable Safety Profile Over A 36-Month Period

뉴스 본문을 불러오고 있어요.

Cumberland Pharmaceuticals Shares Updated Trial Results For Duchenne Muscular Dystrophy Heart Disease Treatment Showing A 30% Reduction In MYL3 And 50% Reduction In MYOD1 With A Favorable Safety Profile Over A 36-Month Period | 웨이프 WAPE

Cumberland Pharmaceuticals Shares Updated Trial Results For Duchenne Muscular Dystrophy Heart Disease Treatment Showing A 30% Reduction In MYL3 And 50% Reduction In MYOD1 With A Favorable Safety Profile Over A 36-Month Period

기사 요약

관련 종목

댓글 —